NCT05650879 2025-07-15
HER2
Enliven Therapeutics
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT04509596 2025-04-01
DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer
Dizal Pharmaceuticals
Phase 1 Completed
NCT01983501 2020-09-21
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
Seagen Inc.
Phase 1 Completed
NCT02605915 2020-02-05
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT03153163 2018-11-23
Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT00928330 2016-11-02
Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy
Genentech, Inc.
Phase 1 Completed
NCT01513083 2016-11-02
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Hoffmann-La Roche
Phase 1 Completed
NCT00932373 2015-08-26
A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen
Genentech, Inc.
Phase 1 Completed
NCT00991562 2014-11-21
IMGN901 in Combination With Lenalidomide and Dexamethasone
ImmunoGen, Inc.
Phase 1 Completed